Business Wire

Brand Finance Global 500 2025: Apple Is the Most Valuable Brand in the World, NVIDIA Enters Top Ten

21.1.2025 17:22:00 EET | Business Wire | Press release

Share

Apple is once again the world’s most valuable brand. Brand Finance, the world’s leading brand valuation consultancy, values Apple’s brand at USD574.5 billion, ahead of second-placed Microsoft (USD461 billion).

According to Brand Finance’s research, four out of the five most valuable brands in the world are technology brands:

  1. Apple: brand value of USD574.5 billion, up 11% from 2024
  2. Microsoft: USD461.1 billion, up 35%
  3. Google: USD413.0 billion, up 24%
  4. Amazon: USD356.4 billion, up 15%
  5. Walmart: USD137.2 billion, up 42%

Brand Finance also analysed what brands have grown the most since 2020, plus TikTok – although Brand Finance began valuing the brand in 2022, its 79% growth in four years puts it in the same league as the other high-growth brands.

  1. TikTok/Douyin: USD105.8 billion, up from USD59.0 billion (in 2022)
  2. DraftKings: USD5.1 billion, up from USD18 million
  3. FanDuel: USD7.0 billion, up from USD56 million
  4. NVIDIA: USD87.9 billion, up from USD4.7 billion
  5. AMD: USD11.0 billion, up from USD1.4 billion
  6. Pinduoduo: USD13.0 billion, up from USD2.5 billion
  7. BYD: USD14.0 billion, up from USD3.1 billion
  8. Apple: USD574.5 billion, up from USD140.5 billion
  9. TSMC: USD34.2 billion, up from US8.6 billion
  10. Microsoft: USD461.1 billion, up from USD117.1 billion
  11. Lilly: USD8.0 billion, up from USD2.1 billion

American gambling brands DraftKings and FanDuel are cashing in as online gambling becomes legal in more American states. Semiconductor brands NVIDIA, AMD, and TSMC advance new technologies, while tech giants Apple and Microsoft lead from the front.

David Haigh, Founder & CEO, Brand Finance, commented:

“Our analysis of what brands have grown the most since 2020 reveals that technology companies do not have a monopoly on sustained brand growth. This also reinforces another global trend: how Chinese brands like TikTok, Pinduoduo, and BYD lead the charge by creating value and challenging established brand leaders.”

e& is the world’s fastest growing brand value, posting an eight-fold increase following consolidation of brand architecture.

WeChat is the strongest brand, with a Brand Strength Index score of 95.2/100.

View the full Brand Finance Global 500 2025 report here

See details of Brand Finance’s methodology here, along with frequently asked questions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121799865/en/

Contacts

Jamie Hyman
press@brandfinance.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye